High Net Worth Advisory Group’s Cytokinetics CYTK Stock Holding History

High Net Worth Advisory Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Hold	5,000	–	–	0.09%	173
2026 Q1	$330K	Hold	5,000	–	–	0.08%	184
2025 Q4	$318K	Hold	5,000	–	–	0.07%	182
2025 Q3	$275K	Buy	+5,000	New	+$206K	0.07%	197
2025 Q2	–	Sell	-5,000	Closed	-$201K	–	228
2025 Q1	$201K	Hold	5,000	–	–	0.06%	212
2024 Q4	$235K	Hold	5,000	–	–	0.07%	197
2024 Q3	$264K	Hold	5,000	–	–	0.07%	188
2024 Q2	$271K	Hold	5,000	–	–	0.08%	173
2024 Q1	$351K	Hold	5,000	–	–	0.11%	143
2023 Q4	$417K	Buy	+5,000	New	+$181K	0.16%	124
2023 Q1	–	Sell	-5,000	Closed	-$229K	–	273
2022 Q4	$229K	Hold	5,000	–	–	0.09%	171
2022 Q3	$242K	Hold	5,000	–	–	0.1%	161
2022 Q2	$196K	Hold	5,000	–	–	0.08%	186
2022 Q1	$184K	Hold	5,000	–	–	0.07%	193
2021 Q4	$228K	Buy	+5,000	New	+$193K	0.08%	178

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

High Net Worth Advisory Group's CYTK Position: Q2 2026 in Review

High Net Worth Advisory Group held its Cytokinetics (CYTK) position steady in Q2 2026 at 5,000 shares worth $426K. The position accounts for 0.09% of the portfolio, ranked #173.

High Net Worth Advisory Group first reported a position in CYTK in Q4 2021 and has held it in 15 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

High Net Worth Advisory Group held 5,000 shares of Cytokinetics worth $426K as of Q2 2026.
High Net Worth Advisory Group left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 0.09% of High Net Worth Advisory Group's portfolio in Q2 2026, its #173 holding.
High Net Worth Advisory Group first reported a position in Cytokinetics in Q4 2021 and has held it in 15 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on High Net Worth Advisory Group's 13F filing for Q2 2026, filed 29 Jul 2026.